Particle.news

Download on the App Store

Argentina Flags 27%–30% Overpricing at Disability Agency as Probe Widens

The early findings strengthen the case for bringing the disability agency under direct Health Ministry control.

Overview

  • A preliminary audit ordered by interventor Alejandro Vilches found ANDIS paid roughly 27% to 30% more across seven high‑cost medicines than comparable Health Ministry purchases.
  • The clearest case cited compares PEG asparaginase bought for $13,500,176 by Incluir Salud in August 2025 with an $8,274,027 Health Ministry price in August 2024, with officials asserting a 27% gap after inflation.
  • ANDIS remains under intervention as the Executive advances plans to end its decentralized status and centralize oversight within the Health Ministry.
  • Health Minister Mario Lugones rejected claims of irregular contracts with Suizo Argentina, saying a headline 78,267 million‑peso award covers logistics services with a two‑year spending cap rather than drug purchases.
  • Scrutiny has widened beyond ANDIS as judicial probes target Suizo Argentina with raids and seizures, and records show the intervened health fund Osprera paid the company about 7,700 million pesos over five months for costly oncology drugs.